The Global Voices in Renal Oncology (VIRO) has officially concluded, marking two days of groundbreaking dialogue and collaboration across the field of kidney cancer. Co-chaired by Prof. Rana McKay and Prof. Yüksel Ürün, the congress brought together leading experts, researchers, clinicians, and advocates from every corner of the globe.
Chair
Co-Chair
From the very first session, the discussions highlighted the importance of innovation, evidence-based practice, and global collaboration in Renal Oncology. Day 1 set the stage with insights into systemic therapies, immuno-oncology, and future treatment directions, while Day 2 closed with impactful talks on variant histologies, emerging agents, palliative care, and the crucial role of advocacy. Thought leaders such as Dr. Axel Bex, Dr. Brad McGregor, Dr. Ari Hakimi, Dr. Wenxin Xu, Dr. Sumanta Pal, Dr. Pedro Barata, and many others shared their perspectives, offering both practical guidance and visionary ideas for the future of renal oncology.
The influence of VIRO 2025 extended far beyond the virtual venue, sparking meaningful engagement across global digital platforms. The congress became a hub of real-time interaction, drawing participation from clinicians, researchers, and advocates around the world. It proved that when a community comes together – whether online or in person – it holds the power to create lasting change and shape the future of oncology. VIRO 2025 demonstrated that collaboration knows no borders; what unites experts is not geography, but a shared commitment to progress, compassion, and the relentless pursuit of better outcomes for patients everywhere.
Have a look on Day 1 highlights covered by OncoDaily here.
For the Day 2 highlights follow the link here.
The success of VIRO 2025 was not only measured by its scientific achievements, but also by the collaboration and support that made it possible. We extend our heartfelt thanks to our partners and sponsors whose support made VIRO 2025 possible:
- Platinum Sponsor: UC San Diego Health
- Gold Sponsor: P53 Inc.
- Bronze Sponsor: AVEO Oncology
- Innovation Supporter: Arcus Biosciences
As Prof. Rana McKay emphasized, the mission of VIRO goes beyond sharing data,
“… it’s about uniting voices worldwide to shape the future of kidney cancer care.”
The collaborations formed here, the knowledge exchanged, and the advocacy amplified will continue to inspire progress long after the congress has ended.
We are pleased to highlight some of the reflections shared by participants on their LinkedIn accounts:
“A moment to recognize the important work by oncology professionals in Bosnia and Herzegovina Svaka čast.
These experts are leading the charge to provide the best possible treatment options and support for patients. It’s wonderful to know our little heart shaped country is in great hands.
VIRO 2025 may be over, but its impact is only beginning. Thank you to everyone who joined us, see you next year for another powerful gathering of global voices in renal oncology.”
“I was pleased to share Moroccan voice in renal oncology, state of art, challenges, and hopes.”
“It was a pleasure to share the stage with global leaders in renal cancer. Thanks OncoDaily for this opportunity”
VIRO 2025 may be over, but its impact is only beginning. Thank you to everyone who joined us, see you next year for another powerful gathering of global voices in renal oncology.
Read More about VIRO 2025.
Written by Sergey Badalyan, MD